

10/657,910

=>  
Uploading C:\Program Files\Stnexp\Queries\10657910a.str

L1 STRUCTURE UPLOADED

```
=> d 11  
L1 HAS NO ANSWERS  
L1 STR
```

G1 O, N  
G2 C, H, Ch, Cy, Hv

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam  
SAMPLE SEARCH INITIATED 15:47:37 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 10029 TO ITERATE

19.9% PROCESSED 2000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00:00:01 3 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 194577 TO 206583  
PROJECTED ANSWERS: 68 TO 532

12 3 SEA SSS SAM 11

10/923,271

```
=> s 11 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 15:47:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 202095 TO ITERATE
```

```
100.0% PROCESSED 202095 ITERATIONS 114 ANSWERS
SEARCH TIME: 00.00.15
```

L3 114 SEA SSS FUL L1

```
=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
186.84 189.54
```

```
FILE 'CAPLUS' ENTERED AT 15:48:24 ON 17 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 17 Nov 2009 VOL 151 ISS 21
FILE LAST UPDATED: 16 Nov 2009 (20091116/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009
```

Cplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/Cplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

```
=> s 13
L4 7 L3
=> s 14 and py2004
```

10/923, 271

0 PY2004  
L5 0 L4 AND PY2004

=> s 14 and py2003  
0 PY2003  
L6 0 L4 AND PY2003

=> s 14 and py <2004  
24043635 PY <2004  
L7 2 L4 AND PY <2004

=> d 1-2 ibib abs hitstr  
THE ESTIMATED COST FOR THIS REQUEST IS 11.28 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y


L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:964817 CAPLUS  
DOCUMENT NUMBER: 141:410756  
TITLE: Preparation of macrocyclic compounds for the treatment  
of inflammation and autoimmune disorders  
INVENTOR(S): Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita,  
Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange,  
Jean-Christophe; Inoue, Atsushi; Kawada, Megumi;  
Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura,  
Akifumi; Kotake, Makoto; Kubo, Yoshikazu; Matsushima,  
Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai,  
Hideki; Shen, Yong-chun; Shirota, Hiroshi; Spyvee,  
Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto,  
Satoshi; Yoneda, Naoki  
PATENT ASSIGNEE(S): Japan  
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl.  
No. PCT/US03/07377.  
CODEN: USXKC0  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224936	A1	20041111	US 2003-657910	20030909
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
WO 2005023792	A2	20050317	WO 2004-US29196	20040909
WO 2005023792	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, HR, HI, DU, IL, IN, IS, JP, KE, KG, KP, KR, LZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NT,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TA,  
 TI, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,  
 BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

JP 2008297317 A 20081211 JP 2008-194192 20080728  
PRIORITY APPLN. INFO.: US 2002-362883P P 20020308  
US 2002-380711P P 20020514  
WO 2003-US7377 A2 20030307  
JP 2003-574642 A3 20030307  
US 2003-657910 A 20030909

OTHER SOURCE(S): CASREACT 141:410756; MARPAT 141:410756  
GI



**AB** Macrocyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.]; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH2; n = 0-2; X = absent, O, NH, N-alkyl, CH2, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NE- $\kappa$ B with IC50 values < 10 $\mu$ M.

IT	603039-45-8P	603045-38-1P	603045-40-5P
	603045-42-7P	603045-44-9P	603045-46-1P
	603151-24-2P	603151-32-2P	603151-34-4P
	603959-45-1P	603985-37-1P	603985-63-3P
	603985-65-5P	603985-69-9P	603985-71-3P
	603985-72-4P	603985-73-5P	603985-74-6P
	603985-75-7P	603985-77-9P	603985-78-0P
	603986-04-5P	603987-34-4P	603987-35-5P
	603987-75-3P	603987-93-5P	603988-36-6P

791101-13-8P 791101-14-9P 791101-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-  
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-  
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-  
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603985-37-1 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603985-63-3 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-  
 dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603985-65-5 CAPLUS  
 CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]-(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)-(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603985-72-4 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603985-73-5 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603985-74-6 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

 $\approx O$ 

RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

 $\equiv O$ 


RN 603985-78-0 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603986-04-5 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxazacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxazacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603987-75-3 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603987-93-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-  
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603988-36-9 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-  
dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotradecin-1,7(8H)-dione,  
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 791101-14-9 CAPLUS

CN 1H-2-Benzoxacyclotetradein-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-  
(methylamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 791101-15-0 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD  
 (1 CITINGS)

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:737744 CAPLUS

DOCUMENT NUMBER: 139:261090

TITLE: Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses

INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.; Diepitrro, Lucian; Du, Hong; Eguchi, Yoshihito; Fujita, Masanori; Gilbert, Sandra; Goto, Masaki; Harmange, Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada, Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan; Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi Eisai Co. Ltd., Japan; et al.

PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 438 pp.

CODEN: PIXXD2 DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BE, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2478065 A1 20030918 CA 2003-2478065 20030307 <--  
 AU 2003224672 A1 20030922 AU 2003-224672 20030307 <--  
 BR 2003008113 A 20050209 BR 2003-8113 20030307  
 EP 1507773 A1 20050223 EP 2003-721353 20030307  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005519954 T 20050707 JP 2003-574642 20030307  
 CN 1653059 A 20050810 CN 2003-810248 20030307  
 NZ 535101 A 20070727 NZ 2003-535101 20030307  
 RU 2334744 C2 20080927 RU 2004-129755 20030307  
 US 20040224936 A1 20041111 US 2003-657910 20030909  
 IN 2004KN01270 A 20060714 IN 2004-KN1270 20040830  
 ZA 2004007156 A 20061227 ZA 2004-7156 20040907  
 MX 2004008722 A 20050713 MX 2004-8722 20040908  
 NO 2004004256 A 20041207 NO 2004-4256 20041007  
 US 20060247448 A1 20061102 US 2004-507067 20041110  
 JP 2008297317 A 20081211 JP 2008-194192 20080728  
 PRIORITY APPLN. INFO.: US 2002-362883P P 20020308  
 US 2002-380711P P 20020514  
 JP 2003-574642 A3 20030307  
 WO 2003-US7377 W 20030307

OTHER SOURCE(S): MARPAT 139:261090

GI



AB Macrocyclic lactones and lactams, such as I [R1 = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R2, R3 = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R1R2 or R1R3 = 3-8 membered alicyclic ring; R4 = H, halogen; R5 = H, hydroxyl protecting group, linked prodrug; R6, R7 = H, OH, protected hydroxyl; R8, R9, R10, R11 = H, OH, NH2, alkoxy, alkylamino, etc.; X = O, NH, S, CH2, etc.; R8R9 = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF- $\kappa$ B, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The prepared macrocycles were assayed for their effect on TNF- $\alpha$  and  $\beta$ -actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells.

IT 791101-13-8 1080810-60-1 1080810-61-2  
 1080810-62-3 1080810-64-5 1080810-65-6  
 1080810-66-7 1080810-68-9 1080810-70-3  
 1080810-71-4 1080810-72-5 1080810-73-6  
 1080810-74-7 1080810-75-8 1080810-76-9  
 1080810-77-0 1080810-78-1 1080810-79-2  
 1080810-80-5 1080810-81-6 1080810-82-7  
 1080810-83-8 1080810-84-9 1080810-85-0  
 1080810-86-1 1080810-87-2 1080810-88-3  
 1080810-89-4 1080810-90-7 1080810-91-8  
 1080810-92-9 1080810-93-0 1080810-95-2  
 1080810-96-3 1080810-97-4 1080810-98-5  
 1080810-99-6 1080811-01-3 1080811-02-4  
 1080811-03-5 1080811-04-6 1080811-05-7  
 1080811-06-8 1080811-07-9 1080811-08-0  
 1080811-09-1 1080811-10-4 1080811-11-5  
 1080811-12-6 1083006-06-7

RL: PRPH (Prophetic)


(Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses)

RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.

10/923, 271




RN 1080810-60-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-61-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-62-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-64-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-65-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-66-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


10/923, 271

Double bond geometry as shown.




RN 1080810-68-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-70-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-71-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


10/923, 271

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-72-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as described by E or Z.



RN 1080810-73-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-74-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


10/923, 271

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-75-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-76-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-77-0 CAPLUS

10/923, 271

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.




RN 1080810-78-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.




RN 1080810-79-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


Double bond geometry as shown.



10/923, 271

RN 1080810-80-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-81-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

$\equiv O$   
RN 1080810-82-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.

10/923, 271



RN 1080810-83-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-84-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A






RN 1080810-85-0 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 1080810-86-1 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 1080810-87-2 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

10/923, 271


Double bond geometry as described by E or Z.



RN 1080810-88-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

$\equiv O$

RN 1080810-89-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-90-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.


PAGE 1-A



PAGE 1-B


$\equiv \text{O}$   
RN 1080810-91-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-92-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-93-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-95-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-96-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080810-97-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080810-98-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


10/923, 271

Double bond geometry as shown.




RN 1080810-99-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-01-3 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-02-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


10/923, 271

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-03-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-04-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923, 271


RN 1080811-05-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-06-8 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-07-9 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



10/923, 271


RN 1080811-08-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-09-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1080811-10-4 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as described by E or Z.



10/923, 271


RN 1080811-11-5 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.




RN 1080811-12-6 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.  
Double bond geometry as shown.



RN 1083006-06-7 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.  
Double bond geometry as shown.



IT 603044-46-8P 603045-38-1P 603045-40-5P  
 603045-42-7P 603045-44-9P, ER 807563  
 603045-45-0P 603045-46-1P 603151-24-2P, ER  
 803064 603151-32-2P 603151-34-4P, ER 804019  
 603959-46-2P, ER 804035 603985-37-1P  
 603985-63-3P 603985-64-4P 603985-65-5P  
 603985-69-9P 603985-70-2P, ER 804606  
 603985-72-4P 603985-73-5P 603985-74-6P  
 603985-75-7P 603985-76-8P 603985-77-9P  
 603985-78-0P 603986-04-5P, ER 804387  
 603987-34-4P 603987-35-5P 603987-75-3P  
 603987-93-5P, ER 806821 603988-36-9P  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)


RN 603044-46-8 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)- (3S,4R,5E,8R,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603045-38-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-  
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-  
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603045-44-9 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 4-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603045-45-0 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-  
 ((methylsulfonyl)oxy)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603045-46-1 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.




RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603151-34-4 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603959-46-2 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4-methyl-,  
(4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-37-1 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603985-63-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-64-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-70-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603985-72-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-  
pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.  
 Double bond geometry as shown.



RN 603985-75-7 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

 $\equiv O$ 

RN 603985-76-8 CAPLUS  
 CN Methanesulfonamide, N-[2-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yloxyethyl]- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 603985-77-9 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

 $\equiv O$ 

RN 603985-78-0 CAPLUS  
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603986-04-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2-  
trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603987-35-5 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,  
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603987-75-3 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,  
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.



RN 603987-93-5 CAPLUS  
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-  
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry as shown.




RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

## Absolute stereochemistry.

Double bond geometry as shown.



IT 603039-45-8P 603959-45-1P 603985-71-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic  
compns. which regulate various genes involved in immune and  
inflammatory responses)

BN 603039-45-8 CAPIUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,10-trihydroxy-14-methoxy-3-methyl-4-(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

## Absolute stereochemistry.

Double bond geometry as shown.




RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxazacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-  
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxazacyclotetradecin-1,7(8H)-dione,  
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-  
(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

10/923,271

REFERENCE COUNT:

6

(6 CITINGS)

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT